Journal
NATURE COMMUNICATIONS
Volume 12, Issue 1, Pages -Publisher
NATURE RESEARCH
DOI: 10.1038/s41467-021-21613-6
Keywords
-
Categories
Funding
- NIH NCI [R01CA227833]
- NIH NIGMS [R01 GM080403]
- 2018 AACR-AstraZeneca Lung Cancer Research Fellowship [18-40-12-DU]
- NIH [R01GM080403, R01GM099842, R01GM073151]
- National Science Foundation [CHE-1753060]
- NIH by a Ruth L. Kirschstein NRSA fellowship [F30DK118774]
- NCI Cancer Center Support Grant/Core Grant [P30CA008748]
- [P30CA086485]
- [UG1CA233259]
- [5P01CA129243-12]
Ask authors/readers for more resources
Understanding oncogenic variants at a mechanistic level helps in the development and optimization of treatment strategies. The study reveals the prevalence of ERBB family KDDs in multiple human cancers, and shows that EGFR-KDD functions through different dimerization modes, with its activity being maximally inhibited by blocking both intra- and inter-molecular dimerization. In conclusion, these findings define a new model of EGFR dimerization and provide important insights for the treatment of EGFR-KDD.
Mechanistic understanding of oncogenic variants facilitates the development and optimization of treatment strategies. We recently identified in-frame, tandem duplication of EGFR exons 18 - 25, which causes EGFR Kinase Domain Duplication (EGFR-KDD). Here, we characterize the prevalence of ERBB family KDDs across multiple human cancers and evaluate the functional biochemistry of EGFR-KDD as it relates to pathogenesis and potential therapeutic intervention. We provide computational and experimental evidence that EGFR-KDD functions by forming asymmetric EGF-independent intra-molecular and EGF-dependent inter-molecular dimers. Time-resolved fluorescence microscopy and co-immunoprecipitation reveals EGFR-KDD can form ligand-dependent inter-molecular homo- and hetero-dimers/multimers. Furthermore, we show that inhibition of EGFR-KDD activity is maximally achieved by blocking both intra- and inter-molecular dimerization. Collectively, our findings define a previously unrecognized model of EGFR dimerization, providing important insights for the understanding of EGFR activation mechanisms and informing personalized treatment of patients with tumors harboring EGFR-KDD. Finally, we establish ERBB KDDs as recurrent oncogenic events in multiple cancers. An EGFR mutant with kinase domain duplication (EGFR-KDD) was previously identified in an index patient, but the functional and therapeutic implications remain unclear. Here, the authors show that KDD occurs in other ErbB receptors in multiple cancers, and characterize the mechanism and inhibition of EGFR-KDD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available